MicroRNA-664a (miR-664a)

MicroRNA-664a is a small, non-coding RNA molecule that regulates gene expression post-transcriptionally, primarily by binding to complementary sequences in the 3′ untranslated regions (3′UTR) of target messenger RNAs and inducing their degradation or inhibiting translation[1][2][5][7][9]. Its expression is dysregulated in several diseases, including hepatocellular carcinoma, where it serves both as an "oncogene" (by suppressing ADH4 and promoting tumor spread) and as a potential biomarker for disease prognosis[1][7]. In neuronal development, miR-664a-5p promotes differentiation, while the precursor form can induce apoptosis via mitochondrial pathways[2][5]. In membranous nephropathy, miR-664a-5p drives disease progression by inhibiting autophagy in podocytes[3]. Due to its ability to regulate key biological processes and its altered expression in disease, miR-664a is being actively studied as a therapeutic target and a biomarker for patient selection and monitoring[1][3][5][7].

Other names

miR-664amiR-664a-3pmiR-664a-5phsa-mir-664hsa-mir-664aMIR664AMIR664microRNA 664MIRN664

Inhibitors like antisense oligonucleotides or antagomirs can block miR-664a function, leading to the derepression of its mRNA targets (e.g., ADH4 in HCC). Conversely, synthetic miRNA mimics can restore miR-664a activity if pathologically decreased, thereby influencing gene expression pathways. The fundamental mechanism involves miR-664a binding to the 3'UTR of target mRNAs (e.g., ADH4), which results in mRNA degradation or inhibition of translation.